| P2093 | author name string | Jonathan Shuter | |
| | Ashish Chandwani | |
| P2860 | cites work | The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial | Q28256092 |
| | ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease | Q28369297 |
| | Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials | Q31108441 |
| | ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. | Q31977860 |
| | Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial | Q34647153 |
| | Lopinavir/ritonavir: a review of its use in the management of HIV infection | Q34652472 |
| | British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). | Q36653838 |
| | Class-sparing regimens for initial treatment of HIV-1 infection | Q37454026 |
| | Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients. | Q38427935 |
| | Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. | Q38914178 |
| | Update of the drug resistance mutations in HIV-1: Fall 2006. | Q53250474 |
| | The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. | Q53580804 |
| | Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen | Q56101127 |
| | Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial | Q58291350 |
| | Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction | Q78045189 |
| | Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial | Q79273817 |
| | Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir | Q79466019 |
| | A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen | Q80210009 |
| | Effects of lopinavir-ritonavir combined therapy during the rat pregnancy. Morphological and biochemical aspects | Q80310912 |
| | Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice | Q80446898 |
| | Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. | Q38914190 |
| | Adherence to protease inhibitor therapy and outcomes in patients with HIV infection | Q39605935 |
| | Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients | Q39606435 |
| | HIV-1 protease inhibitors. A review for clinicians | Q41303053 |
| | HIV-protease inhibitors | Q41751665 |
| | Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. | Q42640549 |
| | Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. | Q44043469 |
| | Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia | Q44191601 |
| | Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. | Q44252661 |
| | Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children | Q44360402 |
| | Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance | Q44361062 |
| | The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients | Q44479509 |
| | The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients | Q44540993 |
| | Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures | Q44561806 |
| | A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. | Q44754522 |
| | Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir | Q44827260 |
| | Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus | Q44827288 |
| | Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients | Q44951046 |
| | Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction | Q44973440 |
| | Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection | Q45016085 |
| | Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans | Q45117927 |
| | HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. | Q45187803 |
| | Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra). | Q45245267 |
| | Top stories of 2004. Back to the future: lopinavir/ritonavir as "monotherapy". | Q45270739 |
| | Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial | Q45405108 |
| | Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. | Q45740263 |
| | Human immunodeficiency virus protease inhibitors | Q45751680 |
| | Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen | Q46374842 |
| | Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. | Q46492574 |
| | A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. | Q46746589 |
| | Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial | Q46765423 |
| | Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients | Q46794117 |
| | Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients | Q46807881 |
| | Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores | Q46843318 |
| | Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel | Q50105738 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P921 | main subject | HIV | Q15787 |
| | lopinavir | Q422585 |
| | ritonavir | Q422618 |
| | lopinavir/ritonavir | Q3836750 |
| P304 | page(s) | 1023-1033 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | Lopinavir/ritonavir in the treatment of HIV-1 infection: a review | |
| P478 | volume | 4 | |